Skip to main content

Table 3 Clinic characteristics of validation cohort

From: Urinary small extracellular vesicles derived CCL21 mRNA as biomarker linked with pathogenesis for diabetic nephropathy

  Healthy control (n  =  16) T2DM (n  =  15) DN (n  =  28)
Males 8 (50%) 8 (53%) 14 (50%)
Age (years) 38 (25–58) 51.8 (40.5–67.6) 59 (51–69)
BMI (kg/m2) 22.1 (20.62–23.71) 25.69 (23.60–28.52) * 24.48 (22.12–27.99)*
Total cholesterol (g/L) 4.71 (4.19–5.67) 4.48 (3.68–6.89)
Triglyceride (mg/dL) 2.55 (1.59–3.97) 1.89 (1.47–2.32)
BUN (mmol/L) 4.15 (3.53–4.96) 5.99 (4.97–9.1) 12.3 (6.9–17.7)***##
SCr (μmol/L) 78 (68.25–89.5) 79 (68.4–111) 188 (99–254)**#
UA (μmol/L) 307 (274–341) 329 (294–387) 372 (318–495)
Plasma albumin (g/L) 45 (40–50) 42 (40–43) 30 (26.5–35.5)****####
eGFR (ml/min/1.73m2) 86.2 (78.7–97.3) 83.8 (60.2–99.5) 31.8 (18.7–73.6)*#
Urinary ACR (mg/g) 4 (0–28) 43 (2–159) 698 (399–1056)**##
  1. Values are expressed as median (IQR) (Mann–Whitney U test, *p  <  0.05, **p  <  0.01, ***p  <  0.001, ****p  <  0.0001 compared with healthy controls; #p  <  0.05, ##p  <  0.01, ####p  <  0.0001 compared with T2DM)